News

EG BioMed is excited to participate in BIO Asia–Taiwan 2025, one of Asia’s most influential biotech events, taking place from July 24 to 27 at the Taipei Nangang Exhibition Center, Hall 1 (4th Floor). BIO Asia–Taiwan Exhibition 2025 Booth Map – EG BioMed @ BIO Asia–Taiwan 2025 About EG BioMed EG BioMed is dedicated to […]

In 2025, EG BioMed presented its ZFP30-targeting cfDNA methylation blood test, the EG-Pancreatic Blood Test-E1, at the ASCO Annual Meeting. The test demonstrated promising early detection results for pancreatic cancer, particularly among the Western population. This study builds on findings we shared at the AACR Annual Meeting in April 20251, where ZFP30 and ZNF781 were

Enhancing Prognostic Precision: The Role of TMEM240 Methylation in Colorectal Cancer Limitations of Current Testing Methods Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally. Traditional blood-based markers like CEA and CA19-9 often lack the sensitivity and timeliness needed to detect early disease progression or treatment response. There is a clear unmet need

Early Warning for Breast Cancer Metastasis: Molecular Clues from Limitations of Traditional Tests and New Possibilities Breast cancer is the most common cancer among women worldwide, accounting for over one-third of new female cancer cases. Despite advances in treatment, around 20% of early-stage patients still experience metastasis. Traditional markers like CA15-3 and CEA lack sensitivity

Early Detection of Pancreatic Cancer: Unlocking the Power of ZFP30 and ZNF781 Methylation Markers Gaps and Limitations in Pancreatic Cancer Diagnosis Pancreatic cancer is notoriously difficult to detect early, with most cases diagnosed at an advanced stage. Common tumor markers like CA19-9 and CEA often lack the sensitivity and specificity needed to guide timely treatment decisions. Research Advances In

EG BioMed specializes in developing innovative blood-based cancer diagnostics centered on DNA methylation technology. The company has been awarded multiple patents both in the U.S. and internationally, including recent patents for early detection of pancreatic cancer (US 12,258,636 B2) and breast cancer (US 12,203,140 B2). These advancements are supported by globally recognized quality certifications—CLIA Laboratory

EG BioMed was honored to sponsor and participate in PurpleStride 2025, hosted by the Pancreatic Cancer Action Network (PanCAN) on April 26, 2025. The event served as a powerful platform to raise awareness about pancreatic cancer and promote innovation in early detection. The event gathered pancreatic cancer patients, families, clinicians, researchers, and supporters from across

CHICAGO – April 28–29, 2025 – EG BioMed, a biotechnology company specializing in early cancer detection using methylated circulating cell-free DNA, today announced that it will present three scientific abstracts at the upcoming American Association for Cancer Research® (AACR) Annual Meeting 2025. These studies highlight the use of DNA methylation biomarkers for non-invasive cancer detection

In the highly competitive U.S. precision medicine market, partnering with a reliable CLIA-certified laboratory is a key advantage for businesses seeking to rapidly enter the market. EG BioMed’s CLIA-certified laboratory partnership program offers a strategic solution to overcome market bottlenecks and quickly establish a foothold in the U.S. precision medicine sector. (SeeMore) Comprehensive Regulatory Compliance

EG BioMed has been closely collaborating with the Health Management Center of Shuang Ho Hospital. During a recent key meeting, Director Dr. Shih-Yu Ko and Deputy Director Dr. Chen enthusiastically praised and endorsed the early detection technology for pancreatic, colorectal, and lung cancers developed by EG BioMed. This groundbreaking technology, which achieves 90%-99% sensitivity, specificity,